The Medical Treatment of Prolactin and Growth Hormone-Secreting Pituitary Tumours

  • Ioana Lancranjan
Conference paper
Part of the Acta Neurochirurgica book series (NEUROCHIRURGICA, volume 47)


Prolactin (PRL) and growth hormone (GH)-secreting pituitary tumours are the most frequently occurring, diagnosed and treated pituitary tumours49. In a series of 424 cases of secreting pituitary tumours Hardy found 225 PRL-secreting adenomas and 199 GH-secreting adenomas46. The high incidence of PRL and GH-secreting pituitary tumours has been reported by many other groups31, 50, 68, 72.


Growth Hormone Pituitary Adenoma Dopamine Agonist Pituitary Tumour Growth Hormone Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aubourgh MD, Derome PJ, Peillon F, Jedynak CP, Visot A, Le Gentil P, Balagura S, Guiot G (1980) Endocrine outcome after transsphenoidal adenomectomy for prolactinoma: prolactin levels and tumour size as predicting factors. Surg Neurol 14: 141 – 152Google Scholar
  2. 2.
    Barbarino A, De Marinis L, Anile C (1982) Dopaminergic mechanism regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery. Metabolism 31: 1100–1104PubMedCrossRefGoogle Scholar
  3. 3.
    Barnard LB (1986) Reduction of pituitary tumour size in acromegaly treated with a somatostatin analogue (SMS 201–995): Abst 983 in The 68th Annual Meeting of the Endocrine Society, AnaheimGoogle Scholar
  4. 4.
    Barrow DL, Tindall GT, Kovacs K, Thorner MO, Horvath E (1984) Clinical and pathological effects of bromocriptine on prolactin secreting and other pituitary tumours. J Neurosurg 60: 1 – 7PubMedCrossRefGoogle Scholar
  5. 5.
    Bassetti M, Spada A, Pezzo G, Giannattasio G (1984) Bromocriptine treatment reduces the cell size in human macroprolactinomas: A morphometric study. J Clin Endocr 58: 268–273PubMedCrossRefGoogle Scholar
  6. 6.
    Belforte L, Camanni F, Chiodini PG, Liuzzi A, Massara F, Molinatti GM, Muller EE, Silvestrini F (1977) Long-term treatment with 2 Br-alpha ergocryptine in acromegaly. Acta Endocrinol 85: 235 – 241PubMedGoogle Scholar
  7. 7.
    Bergh T, Nillius SJ (1982) Prolactinomas: follow-up of medical treatment: In: Molinatti GM (ed) Clinical problem: Microprolactinoma. Excerpta Medica, Amsterdam, pp 115 – 130Google Scholar
  8. 8.
    Besser GM, Parke L, Edwards CRW, Forsyth IA, McNeilly AS (1972) Galactorrhoea: successful treatment with reduction of plasma prolactin levels by bromergocryptine. Br Med J 3: 669 – 672PubMedCrossRefGoogle Scholar
  9. 9.
    Besser GM, Wass JAH (1984) The medical treatment of acromegaly. In: Black PL, Zervas NT, Ridgway EC, Martin JB (eds) Secretory tumours of the pituitary gland. Raven Press, New York, pp 155–168Google Scholar
  10. 10.
    Besser GM, Wass JAH, Grossman A, Ross R, Doniach I, Jones AE, Rees LH (1985) Clinical and therapeutic aspects of hyperprolactinemia. In: MacLeod RM, Thorner MO, Scapagnini U (eds) Prolactin. Basic and clinical correlates. Liviana Press, Padova and Springer, Berlin Heidelberg New York, pp 833 – 847Google Scholar
  11. 11.
    Blackwell RE (1985) Diagnosis and management of prolactinomas. Fertil Steril 43: 5 – 16PubMedGoogle Scholar
  12. 12.
    Bonneville JF, Poulignot D, Cattin F, Couturier M, Mollet E (1982) Computed tomographic demonstration of the effects of bromocriptine on pituitary microadenomas size. Radiology 143: 451 – 455PubMedGoogle Scholar
  13. 13.
    Bouloux PMG, Besser GM, Grossman A (1987) Clinical evaluation of lysuride in the management of hyperprolactinemia. Br Med J 294: 1323–1324CrossRefGoogle Scholar
  14. 14.
    Brassion D, Brandi AM, Nousbaum A, Peillon F (1981) Evidence of dopaminergic receptors in human growth hormone (GH)-secreting pituitary adenomas. Acta Endocrinol Suppl. 243 (Copenh) 97: Abst. 411Google Scholar
  15. 15.
    Camanni F, Massara F, Belforte L, Rosatello A, Molinatti GM (1977) Effect of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects. J Clin Endocrinol Metab 44: 465PubMedCrossRefGoogle Scholar
  16. 16.
    Camanni F, Ghigo E, Ciccarelli E (1982) Follow-up of 69 patients after pituitary tumour removal for hyperprolactinemia. Excerpta Med Int Congr Ser 584: 205 – 213Google Scholar
  17. 17.
    Camanni F, Ghigo E, Ciccarelli E, Massara F, Capagnoli C, Molinatti G, Müller EE (1983) Defective regulation of prolactin secretion after successful removal of prolactinomas. J Clin Endocrinol Metab 57: 1270 – 1279PubMedCrossRefGoogle Scholar
  18. 18.
    Chiodini PG, Liuzzi A, Botalla L, Oppizzi G, Muller EE, Silvestrini F (1975) Stable reduction of plasma growth hormone (GH) levels during chronic administration of 2-Br-alpha ergocryptine (CB 154) in acromegalic patients. J Clin Endocrinol Metab 40: 705 – 708PubMedCrossRefGoogle Scholar
  19. 19.
    Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A, Del Pozo E (1987) Medical treatment of acromegaly with SMS 205–295, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab 64: 447 – 450PubMedCrossRefGoogle Scholar
  20. 20.
    Chiodini PG, Cozzi R, Dallabonzana D, Oppizi G, Verde G, Petroncini MM, Liuzzi A, Boccardi E, Lancranjan I (1989) Medical treatment of acromegaly, dopaminergic agonists and long-acting somatostatin. In: Müller E, Cocchi D, Locatelli V (eds) Advances in growth hormone and growth factors research. Pythagora Press Roma, Milano, Springer, Berlin Heidelberg New York Tokyo, pp 423 – 436Google Scholar
  21. 21.
    Ch’ng LJC, Sandler LM, Kraenzlin ME, Burin JM, Joplin CF, Bloom SR (1985) Long-term treatment of acromegaly with a long acting analogue of somatostatin. Br Med J 290: 285 – 297CrossRefGoogle Scholar
  22. 22.
    Cowden EA, Thomson JA (1979) Resolution of hyperprolactinemia after bromocriptine-induced pregnancy. Lancet 1 (letter) 613PubMedCrossRefGoogle Scholar
  23. 23.
    Cozzi R, Chiodini PG, Dallabonzana D, Petroncini M, Verde G, Oppizzi G, Liuzzi A (1986) Effect of SMS 201–995 administered by minipump infusion in acromegaly. International Conference on Somatostatin, Washington, Abst. 64, p 67Google Scholar
  24. 24.
    Crosignani PG, Mattei AM, Galparoli C, Carena M, Spellecchia D (1987) The natural history of idiopatic hyperprolactinemia and microprolactinomas. In: “Prolattina 1987”. Abst. 4. Milano 6–7 NovGoogle Scholar
  25. 25.
    Daya S, Shewchuck AB, Bryceland N (1984) The effect of multiparity on intrasellar prolactinomas. Am J Obstet Gynecol 148: 512 – 515PubMedGoogle Scholar
  26. 26.
    Dietemann JL, Portha C, Cattin F, Mollet E, Bonneville JF (1983) CT follow-up of microprolactinomas during bromocriptine-induced pregnancy. Neuroradiology 25: 133 – 138PubMedCrossRefGoogle Scholar
  27. 27.
    Domingue JN, Richmon IL, Wislon CB (1980) Results of surgery in 114 patients with prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 137: 102 – 107PubMedGoogle Scholar
  28. 28.
    Eversmann T, Fahlbusch R, Rjosk HK, von Werder K (1979) Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas. Acta Endocrinol (Copenh) 92: 413Google Scholar
  29. 29.
    Faglia G, Nissim M, Giannattasio G, Moriondo P, Travaglini P, Ambrosi B, Bernasconi V, Giovanelli MA, Vaccari U (1982) Medical therapy of prolactinomas: effects of bromocriptine on serum PRL levels and tumour size and morphology. In: Molinati GM (ed) A clinical problem: Microprolactinoma. Excerpta Medica, Amsterdam, pp 131 – 136Google Scholar
  30. 30.
    Fahlbusch R, Giovanelli M, Crosignani PG, Faglia G, Rjosk HK, von Werder K (1980) Differentiated therapy of microprolactinomas: significance of transphenoidal adenomectomy. In: Faglia G, Giovanelli MA, MacLeod RM (eds) Pituitary microadenomas. Academic Press, London, pp 443 – 456Google Scholar
  31. 31.
    Fahlbush R (1980) Surgical failures in prolactinomas. In: Derome PJ, Jedynak CP, Peillon F (eds) Pituitary adenomas, biology, physiopathology and treatment. Asclepios Publishers, France, pp 273 – 284Google Scholar
  32. 32.
    Fahlbush R, Buchfelder M (1985) Transphenoidal operations for prolactinomas. In: Auer LM, Leb G, Tscherne G, Urdl W, Walter GF (eds) Prolactinomas. De Gruyter, pp 209 – 224Google Scholar
  33. 33.
    Faria MAJ, Tindall GT (1982) Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. Results in 100 women with the amenorrhea-galactorrhea syndrome. J Neurosurg 56: 33 – 43PubMedCrossRefGoogle Scholar
  34. 34.
    Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A, Romano C, Boghen M, Dubini A (1986) Long-lasting prolactin lowering effect of cabergoline, a new dopamine agonist in hyperprolactinemic patients. J Clin Endocrinol Metab 63: 941 – 945PubMedCrossRefGoogle Scholar
  35. 35.
    Fleischer N, Guillemin R (1976) Hypothalamic hypophysiotropic hormones. In: Parsons JA (ed) Hypothalamic hypophysiotropic hormones. Peptide hormones. Macmillan Press Limited, London, pp 317 – 335Google Scholar
  36. 36.
    Flückiger E, Briner U, Enz A, Markstein R, Vigouret JM (1983) Dopaminergic ergot compounds: an overview. In: Caine DB, Horrowski R, McDonald W, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 1 – 12Google Scholar
  37. 37.
    Fliickiger E (1986) Pharmacological profile of dopaminomimetic drugs. In: Molinatti L, Martini L (eds) Endocrinology ‘85. Elsevier Science Publishers, North Holland, pp 261 – 271Google Scholar
  38. 38.
    Fossati P, Mazzuca M (1980) Observation of a male patient with prolactinoma treated with long-term bromocriptine therapy alone. In: Derome PJ, Jedynak CP, Peillon F (eds) Pituitary adenomas. Asclepios Publishers, France, pp 305 – 306Google Scholar
  39. 39.
    Frantz AG, Cogen PH, Chang CH, Holub DA, Housepian EM (1981) Long-term evaluation of the results of transsphenoidal surgery and radiotherapy in patients with prolactinomas. In: Crosignani P, Robin BL (eds) Endocrinology of human infertility: new aspects, Academic Press, London, pp 161 – 170Google Scholar
  40. 40.
    Franks S, Jacobs HS (1984) Medical treatment of prolactinomas. In: Jacobs HS (ed) Prolactinomas and pregnancy. Proceedings Special Symposium, XIth World Congress on Fertility and Sterility, Dublin. MTP Press Ltd, Lancaster Boston The Hague Dordrecht, pp 39 – 43Google Scholar
  41. 41.
    Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S (1984) Necrotic changes in prolactinomas after long-term administration of bromocriptine. J Clin Endocrinol 59: 463 – 470CrossRefGoogle Scholar
  42. 42.
    George SR, Kovacs K, Asa SL, Horvath E, Cross EG, Burrow GN (1987) Effect of SMS 201–995, a long-acting somatostatin analogue, on the secretion and morphology of a pitutiary growth hormone cell adenoma. J Clin Endocrinol 26: 395 – 402CrossRefGoogle Scholar
  43. 43.
    Giovanelli M, Gaini SM, Tornei G (1982) Follow-up review of microprolactinomas operated in 48 female patients. Excerpta Med Int Congr Ser 584: 189 – 196Google Scholar
  44. 44.
    Grossman A, Ross R, Wass JAH, Besser GM (1986) Depotbromocriptine treatment for prolactinomas and acromegaly. J Clin Endocrinol 24: 231–238CrossRefGoogle Scholar
  45. 45.
    Hardy J, Beauregard H, Robert F (1978) Prolactin-secreting pitutiary adenomas: Transsphenoidal microsurgical treatment. In: Robyn C, Harter M (eds) Progress in prolactin: Physiology and pathology. Elsevier, Science Publishers, North Holland, pp 361 – 370Google Scholar
  46. 46.
    Hardy J (1980) Ten years after the recognition of pituitary microadenomas. In: Faglia G, Giovanelli MA, MacLeod RM (eds) Pituitary microadenomas. Academic Press, London, pp 7 – 12Google Scholar
  47. 47.
    Jaquet P, Guibout M, Lucioni J, Grisoli F (1978) Hypothalamo pituitary regulation of prolactin in hypersecreting prolactinomas. In: Robyn C, Harter M (eds) Progress in prolactin: Physiology and pathology. Elsevier, Science Publishers, North Holland, pp 371 – 382Google Scholar
  48. 48.
    Kleinberg DL (1984) Medical treatment of pituitary tumours. Sem Reprod Endocr 2: 63–72CrossRefGoogle Scholar
  49. 49.
    Kovacs K, Horvath E (1979) Pathology of pituitary adenomas. Bull Los Angeles Neurol Soc 42: 92 – 110Google Scholar
  50. 50.
    Kovacs K, Horvath E (1980) Pituitary adenomas associated with hyperprolactinemia: morphological and immuno-cytological aspects. In: Faglia G, Giovanelli MA, MacLeod RM (eds) Pituitary microadenomas. Academic Press, London, pp 123 – 131Google Scholar
  51. 51.
    Lamberts SWJ (1984) Antimitotic actions of dopaminergic drugs on human pituitary tumours. In: Müller EE, MacLeod RM (eds) Neuroendocrine perspectives, vol 3. Elsevier Science Publishers, Amsterdam, pp 317 – 343Google Scholar
  52. 52.
    Lamberts SWJ, Witterlinden P, Verschoor L, Van Dongen KJ, Del Pozo E (1985) Longterm treatment of acromegaly with somatostatin analogue SMS 201–995. N Engl J Med 313 – 321, 1576Google Scholar
  53. 53.
    Lamberts SWJ, Uitterlinden P, Del Pozo E (1987) SMS 201995 induces a continuous decline in circulating growth hormone and somatomedin C levels during therapy of agromegalic patients for over two years. J Clin Endocrinol Metab 65: 703 – 710PubMedCrossRefGoogle Scholar
  54. 54.
    Lancranjan I, Rolland R, L’Hermite M (1986) Inhibition of lactation with depot-bromocriptine. In: Angeli A, Bradlow HL, Dogliotti L (eds) Endocrinology of the breast: Basic and clinical aspects. Annals of the New York Academy of Sciences, vol 464, pp 473 – 477Google Scholar
  55. 55.
    Lancranjan I (1987) A new approach to imitate the treatment of patients with prolactinomas. In: Genazzani AR, Volpe A, Facchinetti F (eds) Gynecological endocrinology. The Proceedings of the first International Congress of Gynecological Endocrinology. The Parthenon Publishing Group, Casterton Hall, Carnforth, pp 239 – 252Google Scholar
  56. 56.
    Lancranjan I, Cavagnini F, Felley Ch, Pagani MD, Montini M, Felber JP (1988) Long-term treatment of prolactinomas with a long-acting injectable form of bromocriptine. In: Gena.zzani A (ed) Brain and reproduction. The Parthenon Publishing Group Casterton Hall, Carnforth, pp 569 – 578Google Scholar
  57. 57.
    Landolt AM (1980) Biology of pituitary microadenoma. In: Faglia G, Giovanelli MA, MacLeod RM (eds) Pituitary microadenomas. Academic Press, London, pp 107 – 112Google Scholar
  58. 58.
    Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Silvestrini F (1972) Inhibitory effect of L-dopa on GH release in acromegalic patients. J Clin Endocrinol Metab 35: 941 – 943PubMedCrossRefGoogle Scholar
  59. 59.
    Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, Silvestrini F (1974) Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity of the two respones. J Clin Endocrinol Metab 38: 910 – 912PubMedCrossRefGoogle Scholar
  60. 60.
    Liuzzi A, Chiodini PG, Oppizzi G, Botalla L, Verde G, De Stefano G, Colussi G, Graf KJ (1978) Lisuride hydrogen maleate: evidence for a long-lasting dopaminergic activity in humans. J Clin Endocrinol Metab 46: 196 – 200PubMedCrossRefGoogle Scholar
  61. 61.
    Liuzzi A, Chiodini PG, Oppizzi G, Dallabonzana D, Spelt B, Silvestrini F, Rainer E, Horowski R (1983) Medical treatment of pituitary adenomas: effects on hormonal secretion and tumour size. In: Calne DB, Horrowski R, McDonald W, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 231 – 238Google Scholar
  62. 62.
    Lüdecke DK, Saeger W (1980) Characteristics and surgical problems in prolactinomas in comparison with HGH secreting adenomas. Acta Endocrinol [Suppl] 234: 54 – 55Google Scholar
  63. 63.
    Lüdecke DK, Herrmann HD, Hörmann C, Desaga U, Sager W (1983) Comparison of effects of dopamine agonists and microsurgery in GH and PRL-secreting adenomas. In: Calne DB, Horrowski R, McDonald W, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 271 – 282Google Scholar
  64. 64.
    McGregor AM, Scanlon MF, Hall K, Jall R (1979) Effects of bromocriptine on pituitary tumour size. Br Med J 2: 700 – 703PubMedCrossRefGoogle Scholar
  65. 65.
    Melis GB, Gambacciani M, Paoletti AM, Beneventi F, Mais V, Baroldi P, Fioretti P (1987) Dose related prolactin inhibitory effect of the new long-acting dopamine receptor agonist Cabergoline in normal cycling, puerperal and hyperprolactinemic women. J Clin Endocrinol Metab 65: 41 – 548Google Scholar
  66. 66.
    Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO and The Bromocriptine Study Group (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60: 698 – 705Google Scholar
  67. 67.
    Moriondo P, Travaglini P, Nissim M, Conti A, Faglia G (1985) Bromocriptine treatment of microprolactinomas: Evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60: 764–772PubMedCrossRefGoogle Scholar
  68. 68.
    Mosca L, Solcia E, Capella C, Buffa R (1980) Pituitary adenomas: surgical versus past mortem findings today. In: Faglia G, Giovanelli MA, MacLeod RM (eds) Pituitary microadenomas. Academic Press, London, pp 137 – 149Google Scholar
  69. 69.
    Moses AC, Molitch ME, Sawin CT, Jackson IMD, Biller BJ, Furlanetto R, Reichlin S (1981) Bromocriptine therapy in acromegaly: use on patients resistant to conventional therapy and effect on serum levels of somatomedin-C levels and clinical activity. J Clin Endocrinol Metab 53: 752 – 756PubMedCrossRefGoogle Scholar
  70. 70.
    Nortier JWR, Croughs RJM, Thijssen JHH, Schwarz F (1985) Bromocriptine therapy in acromegaly: effects on plasma GHlevels, somatomedin C levels and clinical activity. J Clin Endocrinol 22: 209 – 217CrossRefGoogle Scholar
  71. 71.
    Peillon F, Cesselin F, Bression D, Zygelman N, Brandi AM, Nousbaum A, Mauborgne A (1979) In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas. J Clin Endocrinol Metab 49: 737 – 744PubMedCrossRefGoogle Scholar
  72. 72.
    Peillon F, Racadot J, Olivier L, Vila-Porcile E (1980) Micro-adenoma, structure and function. In: Faglia G, Giovanelli MA, MacLeod RM (eds) Pituitary microadenomas. Academic Press, London, pp 91 – 105Google Scholar
  73. 73.
    Pieters GFFM, Smals AGH, Kloppenborg PWC (1986) Longterm treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 314: 1391Google Scholar
  74. 74.
    Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E (1984) Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201–995 in acromegaly. Lancet ii: 782 – 791Google Scholar
  75. 75.
    Plewe G, Schezenmeir J, Nölken G, Kruase U, Beyer J, Kasper H, del Pozo E (1986) Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995 over six months. E Klin Wochenschr 64: 389 – 395CrossRefGoogle Scholar
  76. 76.
    Del Pozo E, Neufeld M, Schlüter K, Tortosa F, Clarenbach P, Bieber E, Wendel L, Nüesch E, Marbach P, Cramer H, Kerp L (1986) Endocrine profile of a long-acting somatostatin analogue SMS 205–995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 111: 433–439Google Scholar
  77. 77.
    Rasmussen C, Bergh T, Wide L, Brownell J (1987) CV 205502: A new long-acting drug for inhibition of prolactin hypersecretion. Clin Endocrinol 26: 321–326CrossRefGoogle Scholar
  78. 78.
    Reichin S (1983) Somatostatin. N Engl J Med 309: 1495–1501CrossRefGoogle Scholar
  79. 79.
    Rodman EF, Molitch ME, Post KD, Biler BJ, Reichlin S (1984) Long-term follow-up of transsphenoidal selective adenomectomy for prolactinomas. JAMA 252: 921 – 924PubMedCrossRefGoogle Scholar
  80. 80.
    Rolland R, van der Heijden PFM, Brownell J, van Gennep J (1986) Prolactin lowering effect of CQP 201–403, a new dopamine agonist. In: The 1st International Congress of Neuroendocrinology. Abst. 153. San Francisco, Calif., July, 9 – 11Google Scholar
  81. 81.
    Saitoh Y, Mori S, Arita N, Hayakawa T, Mogami H, Matsumoto K, Mori H (1986) Cytosuppressive effect of bromocriptine on human prolactinomas: stereological analysis of ultrastructural alterations with special reference to secretory granules. Cancer Res 46: 1507 – 1512PubMedGoogle Scholar
  82. 82.
    Serri O, Rasio E, Beauregard H, Hardy J, Somma M (1983) Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinomas. N Engl J Med 309: 280 – 283PubMedCrossRefGoogle Scholar
  83. 83.
    Spada A, Sartorio A, Bassetti M, Pezzo G, Ginnattasio G (1982) In vitro effect of dopamine on growth hormone ( GH) release from human GH-secreting pituitary adenomas. J Clin Endocrinol Metab 55: 734–740PubMedCrossRefGoogle Scholar
  84. 84.
    Thorner MO, Chait A, Aitken M, Benker G, Bloom SR, Mortimer CH, Sanders P, Mason AS, Besser GM (1975) Bromocriptine treatment of acromegaly. Br Med J 1: 299 – 303PubMedCrossRefGoogle Scholar
  85. 85.
    Thorner MO, Evans WS, MacLeod RM, Nunley WC, Rogol D, Morris JL, Besser GM (1980) Hyperprolactinemia: Current concepts of management including medical therapy with bromocriptine. In: Goldstein M, Caine D, Lieberman A, Thorner MO (eds) Ergot compounds and brain function: Neuroendocrine and Neuropsychiatrie Aspects. Raven Press, New York, pp 165 – 189Google Scholar
  86. 86.
    Thorner MO, Burdman JA, Calabrese MT, Valdenegro CA, Vance ML, MacLeod RM (1983) Dopamine agonists and prolactinomas: clinical and basic considerations of the mechanism of action. In: Caine DB, Horrowski R, McDonald W, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 213 – 229Google Scholar
  87. 87.
    Tindall GT, McLanahan CS, Christy JH (1978) Transsphenoidal microsurgery for pituitary tumours associated with hyperprolactinemia. J Neurosurg 48: 849 – 860PubMedCrossRefGoogle Scholar
  88. 88.
    Tindall GT, Kovacs K, Horvath E, Thorner MD (1982) Human prolactin producing adenomas and bromocriptine: A histological immunocytochemical, ultrastructural and morphometrie study. J Clin Endocrinol Metab 55: 1178–1183PubMedCrossRefGoogle Scholar
  89. 89.
    Tramu G, Beauvillain JC, Mazzuca M, Grenier JL, Fossati P, Christiaens JL (1980) Time dependent evolution of pituitary prolactin adenomas under bromocriptine therapy. In: Demme PJ, Jedynak CP, Peillon F (eds) Pituitary adenomas. Asclepios Publishers, France, p 343Google Scholar
  90. 90.
    Tucker HStG, Lankford HV, Gardner DF, Blachard WG (1980) Persistent defect in regulation of prolactin secretion following successful pituitary tumour removal in women with amenorrhea-galactorrhea syndrome. J Clin Endocrinol Metab 51: 968 – 977PubMedCrossRefGoogle Scholar
  91. 91.
    Tucker HSG, Grubb SR, Wigard JP (1982) Galactorrheaamenorrhea syndrome: follow-up of 45 patients after pituitary tumour removal. Ann Intern Med 94: 302 – 307Google Scholar
  92. 92.
    Turkalj I, Braun P, Krupp P (1982) Surveillance criptine in pregnancy. JAMA 247: 1589 – 1591PubMedCrossRefGoogle Scholar
  93. 93.
    Wass JAH, Thorner MO, Morris DV, Rees JH, Mason AS, Jones AE, Besser GM (1977) Long-term treatment of acromegaly with bromocriptine. Br Med J 1: 875 – 878PubMedCrossRefGoogle Scholar
  94. 94.
    Wass JAH, Moult PJA, Thorner MO, Dacie JE, Charlesworth M, Jones ME, Besser GM (1979) Reduction of pituitary tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet ii: 66 – 69Google Scholar
  95. 95.
    Wass JAH, Willians J, Charlesworth M, Kingsley DPE, Halliday M, Doniach I, Rees LH, McDonald WI, Besser GM (1982) Bromocriptine in management of large pituitary tumours. Br Med J 284: 1908 – 1911CrossRefGoogle Scholar
  96. 96.
    Weil C (1986) The safety of bromocriptine in hyperprolactinemic female infertility: a literature review. Curr Med Res Opin 103: 172 – 195CrossRefGoogle Scholar
  97. 97.
    Von Werder K, Eversmann T, Fahlbusch R (1982) Development of hyperprolactinemia in patients with adenomas with or without prior operative treatment. Excerpta Med Int Congr Ser 584: 175 – 188Google Scholar
  98. 98.
    Von Werder K, Fahlbusch R, Rjosk HK (1983) Macroprolactinomas: Clinical and therapeutical aspects. In: Tolis G, Stefanis C, Mountokalakis T, Labrie F (eds) Prolactin and prolactinomas. Raven Press, New York, pp 415 – 422Google Scholar
  99. 99.
    Wollesen P, Andersen T, Karle K (1982) Size reduction of extrasellar pituitary tumours during bromocriptine treatment. Ann Intern Med 96: 281 – 286PubMedGoogle Scholar
  100. 100.
    Winkelman W, Allolio B, Deuss U, Heesen D, Kaulen D, Wileke O (1983) Persistent normoprolactinemia after withdrawal of bromocriptine therapy in patients with prolactinomas. In:_ 3rd European Workshop on Pituitary Adenomas, Amsterdam, The Netherlands, Abst p 9Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Ioana Lancranjan
    • 1
  1. 1.Department of Neuroendocrinology, Clinical ResearchSandoz Ltd.BaselSwitzerland

Personalised recommendations